NDA 021313 · Organon LLC
Clarinex-D 12 Hour
Desloratadine, Pseudoephedrine Sulfate · Oral · Histamine-1 Receptor Antagonist
Last checked: Nov 20, 2026Latest source record: Mar 15, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Feb 1, 2006
Approved uses
1
Original approval plus efficacy supplements
Registered trials
87
28 Phase 3, 4 recruiting
FAERS reports
39
23 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 12, 2025.
CLARINEX-D 12 HOUR is a combination product containing a histamine-1 (H1) receptor antagonist and an alpha adrenergic agonist indicated for: Relief of nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion, in adults and adolescents 12 years of age and older. ( 1.1 ) 1.1 Seasonal Allergic Rhinitis CLARINEX-D ® 12 HOUR Extended Release Tablets is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion, in adults and adolescents 12 years of age and older. CLARINEX-D 12 HOUR Extended Release Tablets should be administered when the antihistaminic properties of desloratadine and the nasal decongestant properties of pseudoephedrine are desired [see Clinical Pharmacology (12) ].
Mechanism: Desloratadine is a long acting tricyclic histamine antagonist with selective H 1 -receptor histamine antagonist activity. Receptor binding data indicate that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 receptor. Desloratadine inhibited histamine release from human mast cells in vitro . Results of a radiolabeled tissue distribution study in rats and a radioligand H 1 -receptor-binding study in guinea pigs showed that desloratadine does not readily cross the blood brain barrier. The clinical significance of this...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- CLARINEX-D 12 HOUR · DESLORATADINE 2.5MG; PSEUDOEPHEDRINE SULFATE 120MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Desloratadine" as an intervention, any sponsor and status, largest first.
- CUTE (Chronic Urticaria Treatment Evaluation)Pivotal-lookingCompleted
UCB PharmaUCB
NCT00264303 · 886 participants · Start Dec 2005 · Primary completion Jan 2007
Drug: Levocetirizine; Desloratadine · For: Chronic Idiopathic Urticaria
Sites: Bruges, Belgium; Brussels, Belgium; Liège, Belgium · 80 sites in all
- LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)Pivotal-lookingCompleted
UCB PharmaUCB
NCT00160589 · 729 participants · Start Apr 2005 · Primary completion Sep 2005
Drug: Levocetirizine · For: Rhinitis, Allergic, Perennial
- Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00783146 · 728 participants · Start Aug 1, 2004 · Primary completion Oct 1, 2004
Drug: desloratadine; fexofenadine and 1 more · For: Seasonal Allergic Rhinitis
- Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00783211 · 722 participants · Start Aug 1, 2004 · Primary completion Oct 1, 2004
Drug: desloratadine; fexofenadine and 1 more · For: Seasonal Allergic Rhinitis
- A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With BilastinePivotal-lookingCompleted
Faes Farma, S.A.Industry
NCT01108783 · 720 participants · Start Apr 2003 · Primary completion Aug 2003
Drug: Bilastine; Desloratadine and 1 more · For: Seasonal Allergic Rhinitis
- Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00405964 · 716 participants · Start Sep 2006 · Primary completion Apr 2008
Drug: 5-mg Desloratadine; Placebo tablet · For: Allergic Rhinitis
- A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01918033 · 608 participants · Start Aug 20, 2013 · Primary completion Jan 26, 2014
Drug: Desloratadine 5 mg; Placebo · For: Perennial Allergic Rhinitis
- Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00406783 · 547 participants · Start Aug 2006 · Primary completion Nov 2007
Drug: 5-mg Desloratadine; Placebo · For: Rhinitis, Allergic, Seasonal; Rhinitis, Allergic, Perennial
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug hypersensitivity4
- nausea4
- dizziness3
- feeling abnormal3
- insomnia3
- malaise3
- product dose omission issue3
- pruritus3
- rash3
- urticaria3
- abdominal discomfort2
- anxiety2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 7 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2015 | 5 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Clarinex-D 12 Hour (Desloratadine/Pseudoephedrine)
2024 spending
$733K
Beneficiaries
397
1,225 claims
Per beneficiary
$1,846
$5.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $126,541 |
| 2022 | $690,361 |
| 2023 | $764,353 |
| 2024 | $732,826 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Efficacy of Mometasone Nasal Spray Combined with Different Doses of Desloratadine, and Montelukast in Childhood Allergic Rhinitis: A Randomized Clinical Trial.
Ghanbari N, Eftekhari K, Samadzadeh-Mamaghani M, et al. · Iran J Allergy Asthma Immunol 2024 · Randomized Controlled Trial, Comparative Study
- The efficacy and safety of H1-antihistamine versus Montelukast for allergic rhinitis: A systematic review and meta-analysis.
Wei C · Biomed Pharmacother 2016 · Comparative Study, Meta-Analysis
- The incidence of sleepiness in newer-generation antihistamine users: a systematic review and network meta-analysis.
Leelakanok N, Pongpun A, Sapapsap B, et al. · Eur J Clin Pharmacol 2026 · Systematic Review, Network Meta-Analysis
- Combining dipyridamole and cilostazol with up-dosing antihistamines improves outcomes in chronic spontaneous urticaria with high D-dimer levels: A randomized controlled trial.
Prasertcharoensuk A, Chongpison Y, Thantiworasit P, et al. · Exp Dermatol 2024 · Randomized Controlled Trial
- Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials.
Canonica GW, Tarantini F, Compalati E, et al. · Allergy 2007 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.
Monroe E, Finn A, Patel P, et al. · J Am Acad Dermatol 2003 · Clinical Trial, Multicenter Study
Sponsor: Organon LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.